December 2016

New Product - Ephedrine Hydrochloride MYX

Ephedrine Hydrochloride MYX (ephedrine hydrochloride) is a sympathomimetic which stimulates both alpha and beta adrenergic receptors, and also releases noradrenaline from its storage site. Ephedrine Hydrochloride MYX Injection is indicated in the treatment of hypotension secondary to spinal anaesthesia. Ephedrine is contraindicated in closed angle glaucoma, since ephedrine may exacerbate the condition. Ephedrine is contraindicated in patients with pheochromocytoma, since severe hypertension may result. Ephedrine is contraindicated in patients with asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis) since the obstruction may increase as myocardial contractility improves. Ephedrine is contraindicated in patients undergoing therapy with monoamine oxidase inhibitors (MAO inhibitors), or within 14 days of ceasing such therapy, since MAO inhibitors may prolong and intensify the cardiac and pressor effects of ephedrine. Ephedrine is contraindicated in patients using linezolid. Ephedrine is contraindicated in patients undergoing general anaesthesia with cyclopropane or halothane or other halogenated hydrocarbons, since anaesthesia may increase cardiac irritability which may lead to arrhythmias. Ephedrine is contraindicated in patients with tachyarrhythmias or ventricular fibrillation, since exacerbation of these conditions may occur. Ephedrine is also contraindicated in patients with hypersensitivity to ephedrine and in patients with psychoneurosis. Ephedrine Hydrochloride MYX is available as a solution for injection in 1 mL ampoules containing 25 mg (equivalent to ephedrine 20.5 mg) in packs of 5’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629